Abbvie ((ABBV)), Abbvie (($CC:ABBV.CUR)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
AbbVie is conducting a Phase 3 clinical study titled A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study With an Open-Label Extension to Evaluate the Efficacy, Safety, and Tolerability of Atogepant for the Preventive Treatment of Menstrual Migraine. The study aims to assess the efficacy, safety, and tolerability of atogepant, an investigational drug, in preventing menstrual migraines. This study is significant as menstrual migraines can severely impact quality of life, and effective preventive treatments are needed.
The intervention being tested is atogepant, an oral tablet designed to prevent menstrual migraines. Participants will receive either atogepant or a placebo during the double-blind period, followed by atogepant during the open-label period.
The study follows a randomized, parallel assignment design with triple masking, meaning the participant, investigator, and outcomes assessor are unaware of the treatment allocations. The primary purpose of the study is treatment-focused.
The study began on February 10, 2025, with primary completion expected shortly thereafter. The last update was submitted on August 4, 2025. These dates are crucial for tracking the study’s progress and anticipating results.
This study update could influence AbbVie’s stock performance positively if atogepant proves effective, as it would enhance their portfolio in the migraine treatment market. Investors should also consider the competitive landscape, as other companies are developing similar treatments.
The study is ongoing, with further details available on the ClinicalTrials portal.